Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.02, 9.01 · 8-K

Churchill Capital Corp XIII

XIIINASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of New Director On October 23, 2026, the board of directors (the “Board”) of Churchill Capital Corp XIII (the “Company”) appointed Paul Lapping as a director of the Board, effective immediately. The Board also appointed Mr.…

Filed Oct 26, 2026Accepted Oct 26, 2026, 4:01 PM EDTCIK 2114229Accession 0001213900-26-112472
Share

Company context

Churchill Capital Corp XIII was founded by Michael Klein, who is also the founder and managing partner of M. Klein and Company, LLC. The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It may pursue an initial business combination target in any business or industry.

Current securities

Recent company filings

  1. 3 filingOct 26, 2026
  2. Other EventsSep 16, 2026
  3. SCHEDULE 13D - filed by CHURCHILL SPONSOR XIII LLC regarding Churchill Capital Corp XIIIAug 7, 2026
  4. Other EventsAug 7, 2026
  5. Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other EventsAug 3, 2026

Registered securities in this filing

CHURCHILL CAPITAL CORP XIII · 8-K · Filed 2026-10-26

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Units, each consisting of one Class A ordinary share and one-tenth of one redeemable warrant

Symbol
XIIIU
Exchange
NASDAQ
Classification
UNIT
Status
Current
Filing context

Context: From2026-10-232026-10-23_custom_UnitsEachConsistingOfOneClassOrdinaryShareAndOnetenthOfOneRedeemableWarrantMember

Dimensions: us-gaap:StatementClassOfStockAxis

Class A ordinary shares, par value $0.0001 per share

Symbol
XIII
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: From2026-10-232026-10-23_custom_ClassOrdinarySharesParValue0.0001PerShareMember

Dimensions: us-gaap:StatementClassOfStockAxis

Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share

Symbol
XIIIW
Exchange
NASDAQ
Classification
WARRANT
Status
Current
Filing context

Context: From2026-10-232026-10-23_custom_WarrantsEachWholeWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50PerShareMember

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000121390026112472 · 3 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 5.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of New Director On October 23, 2026, the board of directors (the “Board”) of Churchill Capital Corp XIII (the “Company”) appointed Paul Lapping as a director of the Board, effective immediately. The Board also appointed Mr. Lapping as a member of the compensation committee and the audit committee of the Board (the “Audit Committee”) and as the chairperson of the Audit Committee, replacing William Sherman, who had served as the interim chairperson of the Audit Committee. Mr. Sherman will continue to serve as a member of the Audit Committee. Mr. Lapping will serve as a member of the first class of directors, which term will expire at the Company’s first annual general meeting. Paul D. Lapping, age 64, is the Manager of Jakal Investments, LLC, a private investment firm he founded in 2005 that focuses on technology, healthcare, fintech, and artificial intelligence sectors. Since April 2015, he has also served as the Manager of Green Pastures Management, LLC, a series LLC with underlying LLC investment vehicles, where he manages and oversees the investment activities of the series and underlying vehicles. He has served as a director of Churchill Capital Corp IX, Churchill Capital Corp XI (Nasdaq: CCXI), and Churchill Capital Corp XII (Nasdaq: CXII), each a special purpose acquisition company (“SPAC”), since April 2025, March 2026, and July 2026, respectively. From August 2025 to February 2026, he also served as a director of Churchill Capital Corp X, a SPAC that completed its business combination with Infleqtion, Inc. in February 2026. From 2011 to 2012, Mr. Lapping served as Chief Operating Officer of Neostellar Capital Corp. (Nasdaq: NSLR) (f/k/a SuRo Capital Corp.), a publicly traded, growth-stage venture capital firm. Prior to that, Mr. Lapping served as a director and Chief Financial Officer of New University Holdings Corp., a capital pool company listed on the TSX Venture Exchange, from August 2010 to August 2011. From October 2009 to May 2011, Mr. Lapping was Chief Financial Officer, Treasurer, Secretary, and a director of 57th Street General Acquisition Corp., a SPAC. Between 2007 and 2009, he served as Chief Financial Officer, Treasurer, and Secretary of Alternative Asset Management Acquisition Corp., also a SPAC. From 1995 to 2003, Mr. Lapping was a General Partner of Minotaur Partners II, L.P. and Merchant Partners, L.P., private equity partnerships focused on middle-market investments. From 1991 to 1995, Mr. Lapping led corporate development at Montgomery Ward Holding Corp., a diversified retail and direct marketing company. From 1988 to 1991, Mr. Lapping worked at Farley Industries, Inc. and its affiliated companies (including Fruit of the Loom, Inc. and West Point-Pepperell, Inc.) in corporate development and finance roles. Earlier in his career, Mr. Lapping worked with Golder, Thoma and Cressey, a private equity firm, and in the mergers and acquisitions group at Salomon Brothers Inc. Mr. Lapping passed the Uniform CPA Examination in 1984. He holds a Bachelor of Science degree from the University of Illinois and an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University. Mr. Lapping is well-qualified to serve as a member of the Board due to his significant operational, financial and leadership experience and experience serving on SPAC boards. No family relationships exist between Mr. Lapping and any other directors or executive officers of the Company. Mr. Lapping is not a party to any arrangements with any other person pursuant to which he was nominated as a director. There are no transactions to which the Company is or was a participant and in which Mr. Lapping has a material interest subject to disclosure under Item 404(a) of Regulation S-K. In connection with their appointments, Mr. Lapping signed a joinder to that certain letter agreement dated as of July 30, 2026, by and among the Company, its officers, its directors and Churchill Sponsor XIII LLC, pursuant to which, among other things, the signatories agreed to waive certain redemption rights and to vote any ordinary shares of the Company they hold in favor of an initial business combination. Mr. Lapping also entered into a standard director indemnity agreement with the Company, a form of which was filed as Exhibit 10.7 to the Company’s Registration Statement on Form S-1 filed with the SEC on July 15, 2026. Director Compensation Agreements On October 23, 2026, the Company entered into a director agreement (“Director Agreement”) with each of William Sherman and Paul Lapping, pursuant to which, in connection with each director’s continuing service as a director of the Company, the Company agreed to pay each director cash compensation of $75,000 per annum, beginning on October 1, 2026. The foregoing summary of the Director Agreements does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Director Agreements, a form of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.